UR TV CAST

The increase in productrevenues for the first quarter of 2009 was primarily attributable to anincrease in the quantity of ZADAXIN sold to China.Research and development expenses for the first quarter of 2009 totaled$5.0 million, compared with $7.5 million for the same period in the prioryear. Thecompletion of enrollment in the RP101 trial ahead of schedule underlinesthe quality of the work of our clinical group and brings us an importantstep closer to unblinding this trial,” said Friedhelm Blobel, Ph.D.,SciClone’s President and Chief Executive Officer. “We look forward toregular progress updates in the coming quarters on our milestones,including profitability in 2009, in-licensing efforts, and to reportingresults from our clinical trials.”Financial ResultsFor the first quarter of 2009, product revenues from the sale of ZADAXINwere $15.1 million, an increase of 42% compared to revenues of $10.6million for the same period in the prior year. We are off to an excellent start in 2009 with our strategy tomanage the company as a profit-driven biopharmaceutical company withattractive upside through its late stage development assets. Executing onour cost-containing clinical development strategy and focused expensemanagement contributed to these better than expected results.

SciClone reported netincome of $0.1 million or $0.00 per share on a basic and diluted basis,compared to a net loss of $5.7 million, or $0.12 per share for the sameperiod of last year.”The continued strong revenue growth from ZADAXIN(R) during the firstquarter allows us to increase our revenue and earnings guidance for thefull year. Revenues for the quarter grew 42%to $15.1 million over the same period last year. FOSTER CITY, CA, May 11 (MARKET WIRE) — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financialresults for the first quarter of 2009.

(Reporting by Anna Driver; Editing by Andre Grenon) Stocks Global Markets. Revenue rose 21 percent to $5.8 billion, but Fluor’sconsolidated backlog fell 7 percent to $29.1 billion from ayear earlier. Fluor, based in Irving, Texas said project cancellations,including at $2.1 billion refinery in Kuwait, is pressuringearnings. For the full year, the company now expects to earn $3.80 to$4.10 per share, down from a prior forecast for $3.90 to $4.20per share. Net earnings were $205 million, or $1.12 per share,compared with $137 million, or 74 cents a share. * Lowers 2009 profit outlook Stocks  |  Global Markets * Q1 net profit up 50 percent HOUSTON, May 11 (Reuters) – Fluor Corp (FLR.N) reported a50 percent rise in first-quarter profit on Monday, but recentproject cancellations prompted the engineering and constructioncompany to lower its full-year profit outlook.